Genetic study of drug-resistant gut bacteria in cancer patients
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at the genetic makeup of hard-to-treat bacteria (carbapenem-resistant Enterobacterales) that cause infections in cancer patients at Sohag Oncology Center. By understanding these bacteria, doctors may better target treatments and improve patient care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are currently admitted at Sohag Oncology Center.
- You have an active infection in any part of the body.
- Your infection is caused by bacteria that are resistant to carbapenem antibiotics (a strong class of antibiotics).
- The bacteria type is confirmed as Enterobacterales, which includes common bacteria like E. coli.
- You agree to have samples (like blood or wound swab) tested for this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at patients with blood cancers who may carry bacteria that are resistant to many antibiotics. It aims to find which patients are more likely to get sick from these bacteria, so doctors can better protect them.
This study looks at new ways to fight antibiotic-resistant bacteria in people with certain common infections. It may help by testing approaches tailored to the specific germs found in your urine, lungs, or deeper infections.
This study looks at how the bacteria in your gut change during cancer treatment (and during some blood stem cell transplants). It may help researchers understand why some people respond differently and guide better future treatment.
This study looks at how chemotherapy or chemoradiotherapy changes the bacteria in your gut. It aims to understand if these changes can make bacteria resistant to antibiotics, which might help improve future cancer care.
This study looks at gut bacteria in people with colorectal cancer that has spread (metastatic). It aims to find patterns in the bacteria that may help doctors choose better treatments.
This study looks at why some healthy people carry resistant bacteria in their gut (called ESBL-producing bacteria). Researchers will collect stool and urine samples and ask about your daily life to find possible risk factors. You won't receive any treatment, but your participation can help scientists understand how to prevent the spread of these bacteria.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.